Genmab | GEN - Passivo Circulante





Passivo Circulante Alterar Data
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Almirall EUR 350.64M 52.12M 2025-12
Amarin USD 179.64M 14.82M 2026-03
Amgen USD 24.96B 534M 2026-03
argenx SE USD 1.32B 278.28M 2025-12
AstraZeneca USD 32.57B 1.95B 2026-03
Bayer EUR 33.46B 875M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Demant DKK 7.42B 1.63B 2025-12
Exelixis USD 370.98M 34.67M 2026-03
Fresenius Medical Care EUR 6.73B 484.42M 2026-03
Genmab DKK 1.43B 686M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
GN Store Nord DKK 4.81B 2.5B 2026-03
GRIFOLS EUR 2.12B 105M 2026-03
Hikma Pharmaceutical USD 1.45B 603M 2025-12
Insmed USD 361.01M 107.87M 2026-03
Lakefront Biotherapeutics EUR 100.42M 52.44M 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck EUR 9.04B 405M 2025-12
Novartis USD 31.37B 4.1B 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
UCB EUR 4.4B 470M 2025-12